血浆PCSK9水平与冠状动脉狭窄程度的相关性研究

吴娜琼; 李莎; 郭远林; 徐瑞霞; 张彦; 朱成刚; 孙静; 卿平; 李建军

doi:10.13201/j.issn.1001-1439.2016.03.012

血浆PCSK9水平与冠状动脉狭窄程度的相关性研究

- 中国医学科学院北京协和医学院国家心血管病中心阜外医院血脂异常与心血管疾病诊治中心(北京, 100037)

详细信息

通讯作者: 李建军,E-mail:13901010368@163.com

中图分类号: R541.4

收稿日期: 2015-08-28

Correlation between plasma PCSK9 levels and the severity of coronary stenosis

- Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China

More Information

Corresponding author: LI Jianjun, E-mail: 13901010368@163.com

Received Date: 28 August 2015

摘要

摘要: 目的:验证血浆前蛋白转化酶枯草杆菌蛋白酶Kexin9型(PCSK9)水平与冠状动脉狭窄程度的相关性。方法:连续入选因心绞痛样胸痛和(或)运动试验阳性接受冠状动脉造影的患者243例,收集基线临床资料,采用ELISA方法检测血浆PCSK9水平。根据标准Gensini积分四分位法将患者分为3组(低分值组0~14,135例;中等分值组25~53,54例;高分值组≥54,54例),对PCSK9水平与冠状动脉狭窄程度的相关性进行分析。结果:与低分值组相比,高分值组患者PCSK9血浆水平显著升高(208.61、217.43、246.81 ng/ml)。血浆PCSK9水平与Gensini积分呈正相关(r=0.191,P=0.003)。经多因素回归分析调整传统危险因素后,证实PCSK9是冠状动脉狭窄程度的独立危险因子(r=0.139,P=0.034)。另外,经非配对检验后发现多支冠状动脉狭窄的患者其PCSK9水平更高(P=0.011)。结论:血浆PCSK9水平与冠状动脉粥样硬化性狭窄的严重程度具有相关性。
- 前蛋白转化酶枯草杆菌蛋白酶Kexin9型 /
- 血脂 /
- 动脉粥样硬化 /
- Gensini积分
Abstract: Objective:To test the hypothesis that plasma PCSK9 levels may be associated with the severity of coronary stenosis. Method:In this cross-sectional study, we consecutively enrolled 243 patients who had angina-like chest pain and/or positive exercise tests and underwent coronary angiography.Baseline clinical characteristics were collected and plasma PCSK9 levels were determined by ELISA. Patients were classified into three groups according to tertiles of standard Gensini score (low group 0~24, n=135; intermediate group 25~53, n=54; high group ≥54, n=54). The relationship between PCSK9 levels and the severity of coronary stenosis were evaluated. Result:Patients in high score group had significant elevated PCSK9 concentrations compared with those in low score group (208.61, 217.43, 246.81 ng/ml, respectively). A positive association between plasma PCSK9 and the Gensini score was found (r=0.191, P=0.003). In multivariate regression analysis, PCSK9 was demonstrated to be an independent factor of coronary stenosis after adjustment for classical risk factors (r=0.139, P=0.034). In addition, patients with muti-vessel stenosis tended to have higher PCSK9 levels according to nonparametric test (P=0.011).Conclusion:Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.
- proprotein convertase subtilisin/kexin type 9 /
- lipid /
- atherosclerosis /
- Gensini score

HTML全文

参考文献(20)

[1]	KULLER L H.Ethnics differences in atherosclerosis,current cardiovascular and lipid metabolism diseases[J].Curr Opin Lipidol,2004,915:109-113.
[2]	LI J J,LI Y S,FANG C H,et al.Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10in patients with unstable angina[J].Heart,2006,92:529-530.
[3]	GUO Y L,LIU J,LI J J,et al.A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice[J].Int J Cardiol,2011,153:211-212.
[4]	FARNIER M.PCSK9:From discovery to therapeutic applications[J].Arch Cardiovasc Dis,2014,107:58-66.
[5]	LAMBERT G,SJOUKE B,CHOQUE B,et al.The PCSK9 decade[J].J Lipid Res,2012,53:2515-2524.
[6]	TAVORI H,FAN D,BLAKEMORE J L,et al.Serum proprotein convertase subtilisin/kexin type 9and cell surface low-density lipoprotein receptor:evidence for a reciprocal regulation[J].Circulation,2013,127:2403-2413.
[7]	URBAN D,PÖSS J,BÖHM M,et al.Targeting the Proprotein Convertase Subtilisin/Kexin Type 9for the Treatment of Dyslipidemia and Atherosclerosis[J].J Am Coll Cardiol,2013,62:1401-1408.
[8]	DENIS M,MARCINKIEWICZ J,ZAID A,et al.Gene inactivation of proprotein convertase subtilisin/kexin type 9reduces atherosclerosis in mice[J].Circulation,2012,125:894-901.
[9]	WU N Q,GUO Y L,XU R X,et al.Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia:laboratory findings and response to lipid-lowering drugs[J].Clin Lab,2013,59:901-907.
[10]	JEAN D,GENEVIÈVE D,NABIL G S.The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis[J].Curr Atheroscler Rep,2010,12:308-315.
[11]	LIU J,GUO Y L,XU R X,et al.Rapid effects of different lipid-lowering drugs on PCSK9 in humans[J].Clin Lipidol,2013,8:519-524.
[12]	GUO Y L,LIU J,XU R X,et al.Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9[J].Clin Drug Invest,2013,33:877-883.
[13]	CHEN S N,BALLANTYNE C M,GOTTO A M JR,et al.A common PCSK9 haplotype,encompassing the E670G coding single nucleotide polymorphism,is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis[J].J Am Coll Cardiol,2005,45:1611-1619.
[14]	HUIJGEN R,BOEKHOLDT S M,ARSENAULT B J,et al.Plasma PCSK9 Levels and Clinical Outcomes in the TNT(Treating to New Targets)Trial[J].J Am Coll Cardiol,2012,59:1778-1784.
[15]	SINNING C,LILLPOPP L,APPELBAUM S,et al.Angiographic score assessment improves cardiovascular risk prediction:the clinical value of SYNTAX and Gensini application[J].Clin Res Cardiol,2013,102:495-503.
[16]	LEE C J,LEE Y H,PARK S W,et al.Association of serum proprotein convertase subtilisin/kexin type 9with carotid intima media thickness in hypertensive subjects[J].Metabolism,2013,62:845-850.
[17]	MARIAN A J.PCSK9 as a therapeutic target in atherosclerosis[J].Curr Atheroscler Rep,2010,12:151-154.
[18]	MBIKAY M,SIROIS F,MAYNE J,et al.PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J].FEBS Lett,2010,584:701-706.
[19]	ROUBTSOVA A,MUNKONDA M N,AWAN Z,et al.Circulating pro-protein convertase subtilisin/kexin9(PCSK9)regulates VLDLR protein and triglyceride accumulation in visceral adipose tis-sue[J].Arterioscler Thromb Vasc Biol,2011,31:785-791.
[20]	CHOI S,KORSTANJE R.Proprotein convertases in high-density lipoprotein metabolism[J].Biomark Res,2013,1:27.